Immunotherapy and therapeutic vaccines in HIV infection.
Enferm Infecc Microbiol Clin
; 23 Suppl 2: 84-104, 2005 Jul.
Article
em En, Es
| MEDLINE
| ID: mdl-16373008
ABSTRACT
Resistance to medication, adverse effects in the medium-long term, and cost are important limitations to lifelong adherence to highly active antiretroviral therapy (HAART). The combination of HAART with immune therapy to restore and/or boost immune-specific responses to HIV has been proposed, with the ultimate aim of controlling viral replication in the absence of HAART over long periods. The functional defects of the cellular and humoral responses would explain the lack of control of the immune system over viral replication. Different types of immune-mediated therapy have been investigated to solve these problems, including passive immune therapy, cytokines, structured treatment interruptions, immunosuppressors and therapeutic vaccines. Our still limited knowledge of immune mechanisms which can control HIV viral replication and of the causes of the deterioration of cellular and humoral immunity have produced only modest benefits in immune-mediated therapy, and are therefore confined to research for the time being. The availability of an optimal therapeutic vaccine would be an important scientific advance which could be compared with the arrival of protease inhibitors in clinical practice. Therefore, priority should be given to research in this field.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Vacinas contra a AIDS
/
Imunoterapia
Tipo de estudo:
Clinical_trials
Limite:
Animals
/
Humans
Idioma:
En
/
Es
Revista:
Enferm Infecc Microbiol Clin
Assunto da revista:
DOENCAS TRANSMISSIVEIS
/
MICROBIOLOGIA
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Espanha